Startup SilaGene Aims to Develop U1 Adaptor Gene-Silencing Tech as Therapeutic Platform
September 10, 2009
Startup SilaGene Aims to Develop U1 Adaptor Gene-Silencing Tech as Therapeutic Platform
At this point, however, SilaGene remains a two-man operation in need of financing, and funding from the National Institutes of Health will be vital for the company to generate key in vivo data.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- IDT Wins SBIR Award for Gene Silencing Tech
July 21, 2010 / GenomeWeb Daily News - Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News - Scripps, Novartis Team Uncovers New Details of Guide RNA, Argonaute2 Interaction
May 16, 2013 / Gene Silencing News - Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News